Many ongoing clinical trials have tested humanized monoclonal anti‐CSF1R antibodies and CSF1R inhibitors can be a method of inhibiting TAMs in advanced metastatic solid cancer and hematological malignancies. The gene discussed is CSF1R; the disease is hematologic disorder.